Work

CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study

Year: 2026

Type: article

Abstract: . Cytotoxicity was abrogated in PD-L1 knockout cells, confirming target specificity. PD-L1 CAR-T cells significantly reduced tumor cell viability within multicellular spheroids. Gemcitabine pretreatment upregulated PD-L1 expression and enhanced CAR-T-mediated cytotoxicity. These findings demonstrate the feasibility of second-generation PD-L1 CAR-T cells, demonstrating preclinical efficacy and specificity, and validating a therapeutic strategy that targets the tumor microenvironment for these challenging cancers.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201209